14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
PYPD vs ABOS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PYPD Captures Overall Composite Edge (31.1 SELL vs 49.5 HOLD), While ABOS Leads 2–1 on Growth & Valuation Pillars
PYPD Overall Winner
6-Pillar Tally: PYPD 1 – 2 ABOS (3 Tie)
Matrix Metrics: PYPD 3 – 2 ABOS
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.1/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 3–2 (led by Options & Positioning), while ABOS wins 2–1 across the 6-pillar growth and valuation breakdown. PYPD trades at $6.50 (N/M Forward P/E, 0.0% operating margin) versus ABOS at $0.22 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–2 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs ABOS. Trailing 12-month operating profitability (PYPD 0.0% vs ABOS 0.0%) and valuation multiples (PYPD N/M vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ABOS Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PYPD vs ABOS Key Questions & Quantitative Answers
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.1/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 3–2 (led by Options & Positioning), while ABOS wins 2–1 across the 6-pillar growth and valuation breakdown. PYPD trades at $6.50 (N/M Forward P/E, 0.0% operating margin) versus ABOS at $0.22 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–2 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PYPD and ABOS split Growth & Scale metrics: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $329,000 for ABOS. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABOS.
PYPD and ABOS trade at balanced relative valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus ABOS (-162.7% ROE) capital efficiency.
In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk). By comparison, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 327% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.